Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CRVO
CRVO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CRVO News
CervoMed to Participate in Investor Meetings at Neuro Perspectives Summit
Jun 12 2026
Newsfilter
CervoMed Financing Plan Triggers Stock Price Plunge
Jun 10 2026
stocktwits
CervoMed Secures $10.5 Million Financing to Advance Neflamapimod
Jun 10 2026
Newsfilter
CervoMed Reports Q1 Financial Results with Increased Losses
May 18 2026
seekingalpha
CervoMed Advances Phase 3 Trial for DLB
May 18 2026
Newsfilter
CervoMed Presents New Therapy for Neurodegenerative Disease
Apr 22 2026
Newsfilter
CervoMed Updates on Clinical Trial Progress for Neflamapimod
Apr 07 2026
Newsfilter
CervoMed Reports 2025 Financial Results and Future Catalysts
Mar 18 2026
NASDAQ.COM
CervoMed Reports $27M Net Loss for FY with Revenue Beat
Mar 17 2026
seekingalpha
CervoMed Advances Neflamapimod in Phase 3 Trial for Dementia
Mar 04 2026
Newsfilter
CervoMed's Neflamapimod Approved for ALS Trials
Feb 18 2026
Newsfilter
Biotech Insider Buying Signals Strong, Three Companies Draw Attention
Jan 15 2026
Benzinga
CervoMed's Neflamapimod Shows Significant Improvement in DLB Patients in Phase 2b Trial
Dec 04 2025
Globenewswire
CervoMed Reports New Data on Neflamapimod Clinical Trial, Significant GFAP Reduction
Dec 02 2025
Globenewswire
CervoMed's Neflamapimod Significantly Reduces Neurodegeneration Biomarker GFAP
Dec 02 2025
Newsfilter
CervoMed Inc. (CRVO) Announces Q3 Loss and Falls Short of Revenue Projections
Nov 08 2025
NASDAQ.COM
Show More News
